Q4 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript
Key Points
- Dr. Lal PathLabs Ltd (BOM:539524) reported a strong revenue growth of 16.6% in Q4 FY26 and 12.2% for the full fiscal year, driven by increased sample volumes.
- The company successfully hosted Medllumina 2026, an international medical conference, enhancing its brand equity and scientific leadership.
- Expansion efforts included the addition of 14 new labs and over 1,100 collection centers, positioning the company to meet rising healthcare demands.
- The Swasthfit preventive healthcare brand contributed 27% to total revenue, indicating strong B2C growth.
- The company maintains a strong balance sheet with net cash and cash equivalents of INR1,526 crores, providing liquidity for future growth and M&A opportunities.
- PAT for Q4 FY26 decreased to INR132 crores from INR156 crores in the previous year, reflecting a decline in profit margins.
- The company faced a one-time cost of INR30 crores related to the new labor code, impacting financial results.
- Despite revenue growth, the EBITDA margin for Q4 FY26 was 26.6%, slightly lower than the previous year's margin.
- The acquisition of ShahbazKers in Mumbai, while strategic, is a small asset with limited immediate impact on overall revenue.
- The company anticipates maintaining similar margins of 27% to 28% in the next fiscal year, indicating limited margin expansion potential.
Ladies and gentlemen, good day, and welcome to the Dr. Lal PathLabs' Q4 FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Nishid Solanki from CDR India. Thank you, and over to you, sir.
Thank you. Good evening, everyone, and welcome to Dr. Lal PathLabs' Q4 FY26 earnings conference call. Today we are joined by senior members of the management team, including Mr. Shankha Banerjee, CEO; and Mr. Ved Prakash Goel, Group CFO, and CEO, International Business.
I would like to share our standard disclaimer. Some of the statements made on today's conference call could be forward-looking in nature, and the actual results could vary from these forward-looking statements. A detailed statement in this regard is available in the results presentation, which has been circulated to you and also available on stock exchange website.
I would now like to invite Mr. Shankha Banerjee to share his perspectives. Thank you,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
